Akero
Jonathan Young is Co-Founder and Chief Operating Officer of Akero. Prior to co-founding Akero, Jonathan held roles as a Venture Partner at Apple Tree Partners (ATP) and General Counsel and Vice President of Policy/Advocacy at Braeburn Pharmaceuticals, Inc., an ATP portfolio company. He previously worked as Partner and General Counsel of FoxKiser, a Washington, D.C. law firm specializing in regulatory approval and life cycle management for pharmaceutical and biotechnology companies. Jonathan is an advocate for policies that empower patients and people with disabilities to reach their life goals. In 2009, he was appointed by President Barack Obama, and confirmed by the US Senate, to serve as Chairman of the National Council on Disability, an independent federal agency advising the President and Congress on disability policy; he previously coordinated White House disability policy for President Bill Clinton. He currently serves on the board of directors of the MedStar Health Research Institute. Jonathan holds a Ph.D. in American history from the University of North Carolina at Chapel Hill, and a J.D. from Yale Law School.
This person is not in any offices
Akero
1 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.